MX2015017257A - Composiciones y metodos de inmunizar contra clostridium difficile. - Google Patents

Composiciones y metodos de inmunizar contra clostridium difficile.

Info

Publication number
MX2015017257A
MX2015017257A MX2015017257A MX2015017257A MX2015017257A MX 2015017257 A MX2015017257 A MX 2015017257A MX 2015017257 A MX2015017257 A MX 2015017257A MX 2015017257 A MX2015017257 A MX 2015017257A MX 2015017257 A MX2015017257 A MX 2015017257A
Authority
MX
Mexico
Prior art keywords
difficile
toxin
methods
compositions
subject
Prior art date
Application number
MX2015017257A
Other languages
English (en)
Inventor
Pietrobon Patricia
Foglia Ginamarie
De Bruyn Guy
Gurunathan Sanjay
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of MX2015017257A publication Critical patent/MX2015017257A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Abstract

Esta descripción se refiere a métodos para provocar una respuesta inmunitaria a la toxina de C. difficile A y la toxina B en un sujeto humano adulto. El sujeto puede estar en riesgo de una infección sintomática de C difficile primaria. En algunas realizaciones, un método es para provocar una respuesta inmunitaria contra la toxina C. difficile A y la toxina B en un sujeto humano adulto en riesgo de una infección sintomática de C. difficile primaria, y comprende administrar al sujeto una composición que comprende C. difficile toxoide a y B toxoide al menos tres veces, siendo cada administración alrededor de siente día de diferencia.
MX2015017257A 2013-06-14 2014-06-13 Composiciones y metodos de inmunizar contra clostridium difficile. MX2015017257A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361835246P 2013-06-14 2013-06-14
PCT/US2014/042298 WO2014201346A1 (en) 2013-06-14 2014-06-13 Compositions and methods of immunizing against c. difficile

Publications (1)

Publication Number Publication Date
MX2015017257A true MX2015017257A (es) 2016-11-11

Family

ID=51168412

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015017257A MX2015017257A (es) 2013-06-14 2014-06-13 Composiciones y metodos de inmunizar contra clostridium difficile.

Country Status (12)

Country Link
US (4) US9730994B2 (es)
EP (1) EP3007724B1 (es)
JP (1) JP6691477B2 (es)
KR (1) KR20160020543A (es)
CN (1) CN105611942A (es)
AU (1) AU2014277981B2 (es)
BR (1) BR112015031088A2 (es)
CA (1) CA2915279A1 (es)
MX (1) MX2015017257A (es)
SG (1) SG11201510166YA (es)
TW (1) TWI648063B (es)
WO (1) WO2014201346A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2754446C2 (ru) 2011-04-22 2021-09-02 ВАЙЕТ ЭлЭлСи Композиции, относящиеся к мутантному токсину CLOSTRIDIUM DIFFICILE, и способы их применения
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
SG11201510166YA (en) 2013-06-14 2016-01-28 Sanofi Pasteur Inc Compositions and methods of immunizing against c. difficile
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
KR102625114B1 (ko) * 2017-09-28 2024-01-12 화이자 인코포레이티드 클로스트리디움 디피실레에 대항한 면역 반응을 도출하기 위한 조성물 및 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071759A (en) 1986-05-30 1991-12-10 The United States Of America As Represented By The Secretary Of The Army Hybridoma cell lines and monoclonal antibodies to clostridum difficile toxins A and B
US6969520B2 (en) * 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
WO1999020304A1 (en) * 1997-10-20 1999-04-29 Oravax, Inc. Passive immunization against clostridium difficile disease
HUE037932T2 (hu) * 2007-09-14 2018-09-28 Sanofi Pasteur Biologics Llc Clostridium difficile A és B toxoidjait tartalmazó gyógyászati kompozíciók
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
RU2754446C2 (ru) 2011-04-22 2021-09-02 ВАЙЕТ ЭлЭлСи Композиции, относящиеся к мутантному токсину CLOSTRIDIUM DIFFICILE, и способы их применения
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
GB201206070D0 (en) 2012-04-04 2012-05-16 Health Prot Agency Clostridium difficile antigens
JP2016516721A (ja) 2013-03-15 2016-06-09 サノフィ パストゥール インコーポレイテッド トキソイド、組成物および関連方法
BR112015023469A8 (pt) 2013-03-15 2019-12-03 Sanofi Pasteur Inc toxóides, composições e métodos relacionados
SG11201510166YA (en) 2013-06-14 2016-01-28 Sanofi Pasteur Inc Compositions and methods of immunizing against c. difficile

Also Published As

Publication number Publication date
US9730994B2 (en) 2017-08-15
BR112015031088A2 (pt) 2017-07-25
JP6691477B2 (ja) 2020-04-28
EP3007724B1 (en) 2023-07-05
WO2014201346A1 (en) 2014-12-18
EP3007724A1 (en) 2016-04-20
CA2915279A1 (en) 2014-12-18
US11419930B2 (en) 2022-08-23
JP2016521754A (ja) 2016-07-25
TWI648063B (zh) 2019-01-21
KR20160020543A (ko) 2016-02-23
CN105611942A (zh) 2016-05-25
TW201536314A (zh) 2015-10-01
AU2014277981A1 (en) 2016-01-07
US20200113991A1 (en) 2020-04-16
AU2014277981B2 (en) 2019-06-20
SG11201510166YA (en) 2016-01-28
US20210145956A1 (en) 2021-05-20
US20170304423A1 (en) 2017-10-26
US20160120968A1 (en) 2016-05-05

Similar Documents

Publication Publication Date Title
PH12017502233A1 (en) Formulations for neoplasia vaccines and methods of preparing thereof
PH12016500773A1 (en) Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants or young children born by c-section
MX2015017257A (es) Composiciones y metodos de inmunizar contra clostridium difficile.
NZ630831A (en) Compositions and methods for administration of vaccines against dengue virus
MX351074B (es) Vacunas contra clostridium difficile que comprenden toxinas recombinantes.
MX2016003419A (es) Metodos y composiciones para sindrome respiratorio coronavirus de oriente medio (mers-cov) inmunogenico.
MX352324B (es) Vacunas multivalentes de nanovehiculos sinteticos.
WO2012170753A3 (en) Bovine vaccines and methods
PH12015501716B1 (en) Anti-mycoplasma spp. subunit vaccine
NZ715459A (en) A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same
PH12015501333A1 (en) Method of making a mycoplasma vaccine
BR112015008417A8 (pt) composição imunogênica, vacina, e, uso de uma composição imunogênica
MY189495A (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
MX2016008397A (es) Composicion para usarse en el tratamiento de tos persistente.
IN2013MU00711A (es)
MX2017002803A (es) Coronavirus bovino atenuado y vacunas relacionadas.
MX2015003765A (es) Arterivirus.
MX2018005825A (es) Celulas inmunes modificadas y usos de las mismas.
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
MX2017013564A (es) Formulaciones de glucopiranosil lipido a y alérgenos de cacahuete para administración sublingual.
WO2015051371A3 (en) Haemophilus parasuis vaccine serovar type four
MX364946B (es) Sistema adyuvante mejorado para la administración de vacunas orales.
TR201904585T4 (tr) Göz yorgunluğu ve rahatsızlığını bertaraf etmek ve hafifletmek için göz ferahlatıcı madde.
MX2021003908A (es) Polipeptidos de accion prolongada y metodos para su produccion y administracion.
MX2017016858A (es) Composiciones inmunogenicas.